Literature DB >> 14760095

A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.

Rongbao Zhao1, Feng Gao, Marie Hanscom, I David Goldman.   

Abstract

Whereas the major folate transporter, the reduced folate carrier (RFC), has a physiological pH optimum, transport activities for folates and antifolates have been detected with low pH optima. Because the interstitial pH in solid tumors is generally acidic, the mechanisms by which antifolates are transported at low pH could be an important determinant of drug activity under these conditions. The current study quantitated the low pH methotrexate (MTX) transport activity in human solid tumor cell lines from the National Cancer Institute tumor panel and other sources. MTX influx at pH 5.5 was equal to, or greater than, influx at pH 7.4 in 29 of 32 cell lines. To assess the role of RFC in transport at low pH in one of these cell lines, a HeLa clonal line (R5) was selected for MTX resistance due to a genomic deletion of the carrier gene. MTX influx was depressed by 70% in R5 versus wild-type HeLa cells at pH 7.4. At pH 6.5, influx in these two lines was similar; as the pH was decreased to 5.5 influx increased in both cell lines. Similarly, whereas net MTX uptake over 1 h was markedly decreased in R5 cells at pH 7.4, net uptake in HeLa and R5 cells was comparable at pH 6.5. Also, as compared with MCF7 breast cancer cells, MTX uptake was markedly decreased at pH 7.4, but only minimally at pH 6.5, in the MDA-MB-231 human breast cancer cell line that lacks RFC expression. When grown with folic acid (2 micro M) at pH 7.4, the IC(50) for MTX was 14-fold higher in R5 as compared with wild-type HeLa cells; the difference was only 4-fold when cells when grown at pH 6.9; the IC(50)s were identical at this pH when the medium folate was 25 nM 5-formyltetrahydrofolate. These data demonstrate that transport activity at low pH is prevalent in human solid tumors, is RFC-independent in R5 cells and MDA-MB-231 breast cancer cells, and can preserve MTX activity in the absence of RFC at an acidic pH relevant to solid tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760095     DOI: 10.1158/1078-0432.ccr-1066-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6.

Authors:  Mike R Wilson; Sita Kugel; Jenny Huang; Lucas J Wilson; Patrick A Wloszczynski; Jun Ye; Larry H Matherly; Zhanjun Hou
Journal:  Biochem J       Date:  2015-04-16       Impact factor: 3.857

2.  The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.

Authors:  Michele Visentin; Ersin Selcuk Unal; Rongbao Zhao; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-24       Impact factor: 3.333

3.  Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.

Authors:  Rongbao Zhao; Michele Visentin; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-07       Impact factor: 3.333

4.  Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.

Authors:  Christina Cherian; Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-15       Impact factor: 3.333

Review 5.  Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.

Authors:  Rongbao Zhao; Larry H Matherly; I David Goldman
Journal:  Expert Rev Mol Med       Date:  2009-01-28       Impact factor: 5.600

6.  A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis.

Authors:  Rongbao Zhao; Sang Hee Min; Yanhua Wang; Estela Campanella; Philip S Low; I David Goldman
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

7.  A humanized mouse model for the reduced folate carrier.

Authors:  David Patterson; Christine Graham; Christina Cherian; Larry H Matherly
Journal:  Mol Genet Metab       Date:  2007-11-05       Impact factor: 4.797

8.  Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial.

Authors:  Xiao-Xiao Dinglin; Yan Huang; Hui Liu; Yin-Duo Zeng; Xue Hou; Li-Kun Chen
Journal:  J Neurooncol       Date:  2013-02-19       Impact factor: 4.130

9.  Functional roles of the A335 and G338 residues of the proton-coupled folate transporter (PCFT-SLC46A1) mutated in hereditary folate malabsorption.

Authors:  Daniel Sanghoon Shin; Rongbao Zhao; Andras Fiser; David I Goldman
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-25       Impact factor: 4.249

10.  N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT).

Authors:  Ersin Selcuk Unal; Rongbao Zhao; Andong Qiu; I David Goldman
Journal:  Biochim Biophys Acta       Date:  2008-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.